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Accepted 17 December 2013Endometrial cancer, with two different types (Type I and Type II)
reported, usually affects postmenopausal women, with a mean age
at diagnosis of 61 years [1]. Major risk factors for endometrial
cancer are increasing age, exposure to unopposed estrogens,
metabolic syndrome, years of menstruation, nulliparity, and
tamoxifen therapy [2]. Endometrioid-type endometrial cancer
(Type 1) is often secondary to overexposure of estrogen, through
either self-production or iatrogenic prescription [3]. Because there
is a strong relationship between unopposed estrogen and endo-
metrial cancer, hormone use in women with an intact uterus often
requires the combination of estrogen and progestin (EPT) [4];
however, many adverse events or side effects have been noted in
women who are treated with EPT [5]. Therefore, transient topical
use of vaginal estrogen cream, especially in the management of the
female lower genital tract due to estrogen deﬁciency-induced se-
nile vaginitis, is common based on the reported efﬁcacy and
extremely low risk of endometrial cancer in these women [6].
Intrauterine devices (IUDs) are a general method of reversible
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verse relationship between IUDs and the risk of endometrial cancer
and the positive relationship between unopposed estrogen and the
risk of endometrial cancer, there may be synergistic, additional, or
independent adverse effects of unopposed estrogen on the endo-
metrial tissue of postmenopausal women after removal of IUDs. In
the following case, we report a 67-year-old woman who presented
rapid growth of endometrial cancer after the removal of an IUD and
transient exposure to estrogen vaginal cream.
A 67-year-old woman, gravida 7, para 6, had a 15-year history of
menopause without hormone therapy. She also had an IUD for
contraception for more than 30 years. The patient denied any
remarkable gynecological or medical history. She reported experi-
encing vaginal discharge and vulvar itching for 3 months and
visited our hospital for help.
A vaginal examination revealed senile changes, dryness of the
vagina, and a smooth cervix with IUD threads at the external os. A
Pap smear was done, and the results were consistent with a diag-
nosis of atrophic vaginitis. Transvaginal ultrasound (TVS) showed
an IUD in situ (Fig. 1A). The device, a Lippes Loop IUD, was removed
smoothly without a remarkable ﬁnding. Topical use of one tube of
vaginal estrogen cream (42.5 g conjugated equine estrogen cream)
was prescribed to treat the atrophic vaginitis.
The patient visited our hospital 3 months later, and complained
of intermittent but persistent vaginal spotting for 1 month. Physical
examination showed a coffee-ground discharge on the posterior
fornix. TVS revealed a 3 cm heteroechoic endometrial lesion with
blood ﬂow (Fig. 1B). Dilation and curettage procedures were per-
formed, and the pathological report was adenocarcinoma.
Preoperative evaluation included tumor markers (all within
normal limits: CA-125: 15 U/mL, CA-19-9: 12.51 U/mL, and CEA:
<1.0 ng/mL) and a pelvic computed tomography scan, revealing a
4 cm mass in the endometrium without lymph node involvement.
The patient underwent staging surgery, including total abdominalby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Transvaginal sonography before and after removal of an intrauterine device (IUD). (A) At the patient's ﬁrst visit to our hospital, ultrasound shows a normal uterus with an IUD
in situ (blue arrow); and (B) at the follow-up examination 3 months after removal of the IUD, ultrasound shows an endometrial lesion measuring 33 mm  32 mm  35 mm with
blood ﬂow (red arrow).
Fig. 2. The surgical specimen, the uterus with bilateral ovaries and fallopian tubes. The
corpus of the uterus is ﬁlled with a papillary irregular friable tumor measuring
66 mm  52 mm  11 mm (red arrow).
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dissection. A papillary friable tumor measuring
66 mm  52 mm  11 mm was found in the corpus of the uterus
(Fig. 2). The histological report revealed adenocarcinoma, endo-
metrioid type, 2009 FIGO Stage IB, Grade 1 [9]. Brachytherapy with
25 grays in ﬁve fractions was applied at the vaginal cuff for 2 weeks.
There was no evidence of recurrence within 24 months after
completion of radiotherapy.
The current present case is highly educational. At ﬁrst, is it
possible that a missing detection of the endometrial cancer before
removing IUDs? The answer is “possible”. However, it was difﬁcult
to investigate, because the thickness of the endometriumwas 6mm
(Fig. 1A), which rarely indicates the pathological ﬁndings of
asymptomatic postmenopausal women. If colored Doppler ultra-
sound could have been applied in this case, although the role of this
approach is uncertain, the additional information might have pro-
vided an early suspicion of the possible lesion. A recent study
showed that a simple Doppler ﬂow score (adding presence of
vascularity, but not a single/double dominant vessel, multiple
vessels, large vessels, and color splash or densely packed vessels)
had an area under the curve of 0.83 [10]. However, the same study
found that to predict endometrial cancer, besides a simple Doppler
ﬂow score, the following parameters, including endometrial
thickness, interrupted endomyometrial junction at TVS with the
addition of an irregular surface at gel infusion sonography, are also
important [10].
Second, the relationship between IUDs and endometrial cancer
is worthy of our attention, because the majority of the studies
favored a “protection”. However, based on the concept that chronic
inﬂammation might contribute to occurrence of neoplastic change,
which has been found in many cancers [11,12], Dossus and col-
leagues [12] found that besides the well-known associations of risk
with sex hormones and insulin-regulated physiological axes, their
data further support the hypothesis that inﬂammation factors play
a role in endometrial carcinogenesis. Nine caseecontrol studies and
one cohort study found reduced risks of endometrial cancer in
patients who had used a nonhormonal IUD [odds ratio (OR) 0.6, 95%
conﬁdence interval (CI) 0.4e0.7] [7]. Moreover, a meta-analysis
found that use of nonhormonal IUDs had a signiﬁcant protective
effect against endometrial cancer (OR 0.54, 95% CI 0.47e0.63) [8].
An inverse association between nonhormonal IUD use and endo-
metrial cancer was observed for the duration of use (OR 0.88 for
5 years) [13]. However, the exact mechanism of the proposed
protective effect of IUD use against endometrial cancer is unclear.
The two primary mechanisms suggested in the literature are a
direct effect on the endometrium, including inﬂammatory changesand effects on endometrial proliferation, which might be respon-
sible for early elimination of abnormal, precancerous, or hyper-
plastic endometrial epithelial cells [14,15], and an effect on the
endometrial response to hormones, including inhibition of estro-
gen and progesterone receptors [7,8]. All IUDs provoke a sterile
inﬂammatory response that modiﬁes the composition of ﬂuids in
the uterine cavity and themorphology of the endometrium, leading
to an increase in the number of neutrophils, mononuclear cells, and
plasma cells [7,8]. In another study, enzymatic and proliferative
activity was signiﬁcantly altered in the endometrium of IUD users
[14]. Copper ions released by copper-bearing IUDs may alter the
action of receptors to steroid hormones in the uterine cavity [13],
and the continuous use of a copper IUD was shown to cause a
signiﬁcant reduction in endometrial mitotic activity and estrogen
receptor concentration [15].
Third, the relationship between the duration of IUDs and the
risk of endometrial cancer or other complications needs further
discussion, because it is unclear whether these or other responses
invoked by an IUD could alter the risk of endometrial cancer
development after the device has been removed. Although we did
not know how long the endometrial cancer had been present in this
patient, we believe that use of an IUD for more than 30 years might
have contributed to the “concealed” or “silent” nature of the
endometrial lesion. For the purpose of safety, a long-term deposi-
tion of IUD without regular change is not suggested.
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effective when used for the relief of vulvovaginal symptoms
[6,15,16]. Short-term and transient use of estrogen cream without
combined progestin has been reported to be safe and effective
[6,17]; however, the long-term effects of vaginal estrogens on the
endometrium remain uncertain [18]. In a study using ovariecto-
mized rats, use of estrogen cream led to a signiﬁcant increase in
uterine weight and in the thickness of the myometrium and
endometrium, and induced histological modiﬁcations in the
endometrium suggestive of estrogenic activity [18]. In the most
recent Cochrane review, two trials showed signiﬁcant endometrial
overstimulation (as evaluated by a progestagen challenge test) in
the conjugated equine estrogen cream group compared to the ring
group (OR 0.29, 95% CI 0.11e0.78), suggesting the potential risk of
conjugated equine estrogen cream [19].
In this case report, the efﬁcacy or safety of the use of transient
vaginal cream is not argued, and the short-term use of vaginal es-
trogen is not indicated as a cause of endometrial cancer. The
endometrial cancer of this patient might be an accidental ﬁnding;
that is to say, the patient's condition might have been biased by
surveillance. However, the fact is that this menopausal woman had
a diagnosis of endometrioid carcinoma of the uterus after she had
been treated with removal of the IUD and a transient 3-month
application of estrogen vaginal cream. Therefore, we should
emphasize the unique nature of this case. Careful evaluation prior
to prescribing estrogen vaginal cream and close monitoring post-
prescription should be emphasized for these women, even
though the risk of endometrial cancer might be low.Conﬂicts of interest
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